Image

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (GVHD) in patients undergoing an allogeneic hematopoietic cell transplant (HCT). HCT is the only curative treatment for some types of blood cancer. Unfortunately, this approach can lead to the development of GVHD, which is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Some research has shown that the bacteria that is present in the dental plaque soon after transplant may affect the development of chronic GVHD. Dental cleanings prior to transplant are part of the normal standard of care for patients undergoing HCT. Adding an additional cleaning shortly after HCT may be effective for preventing the development of chronic GVHD.

Description

OUTLINE

Patients who have not undergone dental cleaning within 3 months preceding the baseline visit undergo dental cleaning at baseline (before the initiation of transplant conditioning) according to standard of care. All patients undergo simplified dental cleaning on day +28 following HCT.

After completion of study intervention, patients are followed up on days +84 and +180 and at 1 year.

Eligibility

Inclusion Criteria:

  • Age ≥ 18 years old
  • T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed. Any conditioning regimen is allowed
  • One of the following HCT donor types:
    • 9/10 or 10/10 human leukocyte antigen (HLA)-matched unrelated donor
    • Cord blood
  • Willing to have an in-person 1-year long-term follow-up (LTFU) visit including an oral medicine at Fred Hutch (FH)
  • Ability to understand and sign a written informed consent document (or legal representative)

Exclusion Criteria:

  • Edentulous state
  • Bone marrow as graft source
  • Use of post-transplantation cyclophosphamide (PTCy) or ruxolitinib as GVHD prophylaxis
  • Use of anti-thymocyte globulin (ATG) in conditioning

Study details
    Chronic Graft Versus Host Disease
    Acute Graft Versus Host Disease
    Hematopoietic and Lymphatic System Neoplasm

NCT07535008

Fred Hutchinson Cancer Center

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.